Improving pediatric multiple sclerosis interventional phase III study design: a meta-analysis

Background: To support innovative trial designs in a regulatory setting for pediatric-onset multiple sclerosis (MS), the study aimed to perform a systematic literature review and meta-analysis of relapse rates with interferon β (IFN β), fingolimod, and natalizumab and thereby demonstrate potential benefits of Bayesian and non-inferiority designs in this population. Methods: We conducted a literature search in MEDLINE and EMBASE from inception until 17 June 2020 of all studies reporting annualized relapse rates (ARR) in IFN β-, fingolimod-, or natalizumab-treated patients with pediatric-onset relapsing–remitting MS. These interventions were chosen because the literature was mainly available for these treatments, and they are currently used for the treatment of pediatric MS. Two researchers independently extracted data and assessed study quality using the Cochrane Effective Practice and Organization of Care – Quality Assessment Tool. The meta-analysis estimates were obtained by Bayesian random effects model. Data were summarized as ARR point estimates and 95% credible intervals. Results: We found 19 articles, including 2 randomized controlled trials. The baseline ARR reported was between 1.4 and 3.7. The meta-analysis-based ARR was significantly higher in IFN β-treated patients (0.69, 95% credible interval: 0.51–0.91) versus fingolimod (0.11, 0.04–0.27) and natalizumab (0.17, 0.09–0.31). Based on the meta-analysis results, an appropriate non-inferiority margin versus fingolimod could be in the range of 2.29–2.67 and for natalizumab 1.72–2.29 on the ARR ratio scale. A Bayesian design, which uses historical information for a fingolimod or natalizumab control arm, could reduce the sample size of a new trial by 18 or 14 patients, respectively. Conclusion: This meta-analysis provides evidence that relapse rates are considerably higher with IFNs versus fingolimod or natalizumab. The results support the use of innovative Bayesian or non-inferiority designs to avoid exposing patients to less effective comparators in trials and bringing new medications to patients more efficiently.

[1]  K. Rose,et al.  Reader Response: Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG , 2020 .

[2]  V. Rivera,et al.  Current Advances in Pediatric Onset Multiple Sclerosis , 2020, Biomedicines.

[3]  Frank Bretz,et al.  Beyond Randomized Clinical Trials: Use of External Controls , 2019, Clinical pharmacology and therapeutics.

[4]  E. Kalbe,et al.  Fatigue and depression predict health-related quality of life in patients with pediatric-onset multiple sclerosis. , 2019, Multiple sclerosis and related disorders.

[5]  M. Moodley,et al.  Newer Treatment Approaches in Pediatric-Onset Multiple Sclerosis , 2019, Current Treatment Options in Neurology.

[6]  P. Gallo,et al.  No evidence of disease activity including cognition (NEDA-3 plus) in naïve pediatric multiple sclerosis patients treated with natalizumab , 2019, Journal of Neurology.

[7]  P. Huppke,et al.  Consistent control of disease activity with fingolimod versus IFN β-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[8]  P. Huppke,et al.  Association of Obesity With Multiple Sclerosis Risk and Response to First-line Disease Modifying Drugs in Children. , 2019, JAMA neurology.

[9]  Anthony O'Hagan,et al.  Predictively consistent prior effective sample sizes , 2019, Biometrics.

[10]  D. Oleske,et al.  Epidemiology of Pediatric-Onset Multiple Sclerosis: A Systematic Review of the Literature , 2019, Journal of child neurology.

[11]  S. Pearson,et al.  New Cost-Effectiveness Methods to Determine Value-Based Prices for Potential Cures: What Are the Options? , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[12]  M. Ünsal.  Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis , 2019, Turkish Journal Of Neurology.

[13]  K. Rose.  The Challenges of Pediatric Drug Development , 2019, Current therapeutic research, clinical and experimental.

[14]  X. Montalban,et al.  Multiple sclerosis: clinical aspects , 2018, Current opinion in neurology.

[15]  E. M. Oliveira,et al.  Pediatric-onset multiple sclerosis in Brazilian patients: Clinical features, treatment response and comparison to pediatric neuromyelitis optica spectrum disorders. , 2018, Multiple sclerosis and related disorders.

[16]  Heinz Schmidli,et al.  Evidence synthesis from aggregate recurrent event data for clinical trial design and analysis , 2018, Statistics in medicine.

[17]  H. Benrhouma,et al.  Pediatric Multiple Sclerosis in Tunisia: A Retrospective Study over 11 Years , 2017, BioMed research international.

[18]  W. Brück,et al.  Interferon beta-1b in treatment-naïve paediatric patients with relapsing–remitting multiple sclerosis: Two-year results from the BETAPAEDIC study , 2017, Multiple sclerosis journal - experimental, translational and clinical.

[19]  R. Alroughani,et al.  The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study. , 2017, Pediatric neurology.

[20]  L. Wilkins.  Neurofilament light chain level is a weak risk factor for the development of MS , 2016, Neurology.

[21]  T. Müller,et al.  Children with multiple sclerosis should not become therapeutic hostages , 2016, Therapeutic advances in neurological disorders.

[22]  Tim Friede,et al.  Meta‐analysis of few small studies in orphan diseases , 2016, Research synthesis methods.

[23]  M. Filippi,et al.  Natalizumab in the pediatric MS population: results of the Italian registry , 2015, BMC Neurology.

[24]  Y. Fragoso,et al.  Fingolimod Prescribed for the Treatment of Multiple Sclerosis in Patients Younger Than Age 18 Years. , 2015, Pediatric neurology.

[25]  Anthony O'Hagan,et al.  Robust meta‐analytic‐predictive priors in clinical trials with historical control information , 2014, Biometrics.

[26]  Jeffrey A. Cohen,et al.  Defining the clinical course of multiple sclerosis: the 2013 revisions. , 2014, Neurology.

[27]  Ludwig Kappos,et al.  Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial , 2014, The Lancet Neurology.

[28]  A. Ghezzi,et al.  Subcutaneous Interferon Beta-1a in Pediatric Multiple Sclerosis , 2013, Journal of child neurology.

[29]  A. Ghezzi,et al.  International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions , 2013, Multiple sclerosis.

[30]  D. Prayer,et al.  Natalizumab therapy for highly active pediatric multiple sclerosis. , 2013, JAMA neurology.

[31]  M. Filippi,et al.  Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases , 2013, Multiple sclerosis.

[32]  W. Rodriguez,et al.  Extrapolation of Adult Data and Other Data in Pediatric Drug-Development Programs , 2011, Pediatrics.

[33]  Christian Confavreux,et al.  Randomized trial of oral teriflunomide for relapsing multiple sclerosis. , 2011, The New England journal of medicine.

[34]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[35]  Ludwig Kappos,et al.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[36]  Ludwig Kappos,et al.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[37]  D. Spiegelhalter,et al.  Summarizing historical information on controls in clinical trials , 2010, Clinical trials.

[38]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.

[39]  C. Pozzilli,et al.  Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience , 2009, Neurological Sciences.

[40]  Lauren B. Krupp,et al.  Consensus definitions proposed for pediatric multiple sclerosis and related disorders , 2007, Neurology.

[41]  S. Tenembaum,et al.  Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis , 2006, Neurology.

[42]  M. Sahraian,et al.  Treatment of Early Onset Multiple Sclerosis with Suboptimal Dose of Interferon Beta-1a , 2006, Neuropediatrics.

[43]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[44]  F. Hanefeld,et al.  Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a , 2005, Neurology.

[45]  E. Waubant,et al.  Interferon Beta-1a in Children with Multiple Sclerosis is Well Tolerated , 2001, Neuropediatrics.

[46]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[47]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[48]  F. Mcdowell,et al.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS , 1965, Annals of the New York Academy of Sciences.

[49]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[50]  L. Ramió-Torrentá,et al.  Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis. , 2013, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[51]  V. Shaygannejad,et al.  Interferon-beta in pediatric multiple sclerosis patients: safety in short-term prescription. , 2012, Acta medica Iranica.

[52]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2009, Journal of clinical epidemiology.

[53]  Frcp,et al.  Pediatric multiple sclerosis Escalation and emerging treatments , 2022 .